

# Peripheral Inflammation Is Associated With Brain SPECT Perfusion Changes in Schizophrenia

**Guillaume Fond**

AP-HM: Assistance Publique Hopitaux de Marseille

**Alexandra GAROSI**

AP-HM: Assistance Publique Hopitaux de Marseille

**Mélanie FAUGERE**

AP-HM: Assistance Publique Hopitaux de Marseille

**Jacques-Yves Campion**

AP-HM: Assistance Publique Hopitaux de Marseille

**Christophe LANCON**

AP-HM: Assistance Publique Hopitaux de Marseille

**Laurent Boyer**

AP-HM: Assistance Publique Hopitaux de Marseille

**Raphaelle RICHIERI**

AP-HM: Assistance Publique Hopitaux de Marseille

**Eric Guedj** (✉ [eric.guedj@ap-hm.fr](mailto:eric.guedj@ap-hm.fr))

CHU Timone <https://orcid.org/0000-0003-1912-6132>

---

## Research Article

**Keywords:** Psychiatry, schizophrenia, mental health, SPECT, brain perfusion, neuroimaging

**Posted Date:** March 17th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-315347/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

**Version of Record:** A version of this preprint was published at European Journal of Nuclear Medicine and Molecular Imaging on August 18th, 2021. See the published version at <https://doi.org/10.1007/s00259-021-05529-3>.

## Abstract

**Purpose.** Peripheral inflammation is frequent in schizophrenia, and plays a major role in pathophysiology, prognosis, and persistence of psychotic symptomatology under treatment.

**Aim.** To determine the correlation between peripheral inflammation and brain SPECT perfusion in stabilized antipsychotic-treated outpatients with schizophrenia, and to determine whether such perfusion changes are correlated to persistent symptoms.

**Methods.** Highly sensitive C-reactive protein blood level (hs-CRP) and brain SPECT perfusion were assessed in 137 stabilized outpatients with schizophrenia. Whole-brain voxel-based associations were searched with SPM between SPECT perfusion and hs-CRP (correlation analysis to quantitative levels and between-group analysis according to a threshold of 3mg/L). The identified clusters were secondarily correlated with clinical symptoms.

**Results.** After adjustment for age, sex, educational level, illness duration, antidepressant, chlorpromazine equivalent dose, tobacco smoking and obesity, a negative correlation was found between hs-CRP level and the perfusion of 4 brain areas: the right inferior frontal gyrus, the right middle/superior temporal gyrus, the left superior parietal lobe and the right postcentral/transverse temporal gyrus ( $p$ -voxel  $< 0.001$ ,  $k > 80$ , uncorrected). An increased perfusion of the left amygdala was found in patients with hs-CRP  $\geq 3$  mg/L compared to those with hs-CRP level  $< 3$ mg/L. A negative correlation was found between perfusion of the right inferior frontal gyrus and the persistence of positive, negative and excitement symptoms under antipsychotic treatment.

**Conclusion.** In stabilized patients with schizophrenia, peripheral inflammation is associated with brain perfusion changes that are correlated with the persistence of psychotic symptomatology.

## Introduction

Elucidating the underlying pathophysiology of schizophrenia may aid in better selection and development of treatments. In the 1970s, monoaminergic theory was the leading nosological theory, hypothesizing that schizophrenia was due to dopamine dysfunctions. This approach has shown its limits as first-line anti-dopaminergic antipsychotics are effective in only 34% of the patients[1] and as clozapine, the most effective antipsychotic, has the lower antidopaminergic potency with an efficiency of only 60% in patients not responding to previous antipsychotic[2]. Current biological hypotheses on persistent psychotic symptoms under treatment focus on differences in the functioning of dopaminergic pathways or changes in glutamate or other neurotransmitter pathways. These views are not mutually exclusive, with several pathways converging and possibly contributing to the neurobiology of persistence of psychotic symptoms under treatment.

In addition to these possible explanations, we have now more than two decades of data highlighting the role of immune-inflammatory processes in schizophrenia. Among them, genome wide studies have shown that the mutation of the Human leukocyte antigen was the most consistent pattern of schizophrenia[3]. An overall increase in expression of proinflammatory genes has been found on transcript and protein level in schizophrenia brain postmortem histology[4]. Schizophrenia patients have multiple sources of inflammation including Toxoplasma infection and overweight[5]. All these results have boosted the immune-inflammatory hypothesis in schizophrenia[6]. While microglial activation induced by peripheral inflammation has been well documented in the post-mortem brain studies of schizophrenia[4, 7], little is known on the consequences of inflammation on living brain perfusion. Our hypothesis is that inflammation may induce alterations of the neurovascular unit (including astrocytes, endothelial cells, and

neurons) which could lead to brain perfusion changes[8]. We also hypothesized that these functional changes would be an indirect marker of persistent psychotic symptoms under antipsychotic treatment.

The main objective of this study is to determine the impact of peripheral inflammation on brain SPECT (single-photon emission computed tomography) perfusion in patients with schizophrenia. The secondary objective is to determine whether these perfusion changes are associated with persistence of psychotic symptomatology under antipsychotic treatment.

## Methods

### Study design

All outpatients were recruited in the regional psychiatric academic hospital from Assistance Publique des Hôpitaux de Marseille (AP-HM) academic hospital (<http://fr.ap-hm.fr/>), Marseille, France, from April 2011. The patients were referred from the whole Provence-Alpes Cotes d'Azur region (South of France) by their general practitioner or psychiatrist, who subsequently received a detailed evaluation report with suggestions for personalized interventions.

### Study population

**Inclusion criteria.** All stabilized outpatients (defined by stable background treatment, i.e., antipsychotic and/or antidepressant for at least 8 weeks without change or dose modification) with an ICD-10 diagnosis of schizophrenia/schizoaffective disorder (F20\*, F25\*) having had a brain SPECT perfusion with  $^{99m}\text{Tc}$ -HMPAO and measurement of highly sensitive C-reactive protein (hs-CRP) were consecutively included.

**Exclusion criteria.** Patients with a history of neurological disorders (including stroke, epilepsy and head injury) or any non-psychiatric concurrent illnesses affecting the central nervous system (such as lupus, rheumatoid arthritis, multiple sclerosis or acute infectious disorder) and patients not speaking French were excluded.

### Sociodemographic, clinical, and treatment variables

The clinical evaluation included diagnostic confirmation by two trained psychiatrists of the Schizophrenia Expert Centres using a structured clinical interview [9] and data on age, sex, educational level (university level defined by > 12 years of education: yes/no), illness duration (years), antidepressant (yes/no), current daily tobacco smoking status (yes/no), obesity (yes/no defined by a body mass index  $\geq 30$ ). Chlorpromazine equivalent doses (CPZ100eq) were calculated according to the minimum effective dose method [10]. Schizophrenic symptomatology was assessed using the Positive And Negative Syndrome Scale (PANSS) [11]. Current depressive symptoms were evaluated using the Calgary Depression Rating Scale for Schizophrenia (CDSS) [12].

### Biological measurements

Hs-CRP was measured by routine blood samples using sensitive regular immunoassays (ELISA). The results were expressed as milligram per litre, and the detection limit was 0.08  $\mu\text{g}/\text{ml}$ . A cut-off of 3 mg/L was used to classify patients as "low-grade peripheral inflammation" ( $\geq 3\text{mg}/\text{L}$ ) vs. "no peripheral inflammation" ( $< 3\text{mg}/\text{L}$ )[13].

### Brain SPECT perfusion procedure

All SPECT perfusion exams were carried out at AP-HM, France and were performed under the same conditions for all patients included in this study. The patients received an intravenous injection of 740 MBq of  $^{99m}\text{Tc}$ -HMPAO after a rest period of 15 minutes in quiet surroundings with their eyes closed. The acquisition was performed 20 minutes later after an additional period of sensorial rest.

SPECT acquisition was performed using the same double-headed rotating gamma-camera (E.cam, Siemens, Erlangen, Germany) equipped with fan-beam collimator to improve sensitivity. The total scan time was 25 minutes with sixty projections per head of 25 s collected in 128 x 128 format. Tomographic 3D reconstruction was performed using a filtered back-projection algorithm.

## Brain SPECT perfusion analyses

A whole-brain voxel-based analysis was performed using SPM8 (Wellcome Trust Centre for Neuroimaging) running on MATLAB (Mathworks Inc.). Images were initially converted from DICOM to NifTi format using MRICro ([www.mricro.com](http://www.mricro.com)) and transferred to Statistical parametric mapping (SPM). Data were standardized with the Montreal Neurological Institute (MNI) atlas using a 12-parameter affine transformation followed by nonlinear transformations and trilinear interpolation. The dimensions of the resulting voxels were  $2 \times 2 \times 2$  mm. Standardized data were smoothed with a Gaussian filter (full-width at half-maximum of 8 mm) to blur individual variations in gyral anatomy and to increase the signal-to-noise ratio. Multiple regression analysis was performed on the whole group of patients including the following variables: age, sex, educational level (university level defined by > 12 years of education: yes/no), illness duration (years), antidepressant (yes/no), chlorpromazine equivalent dose (mg/d), current daily tobacco smoking status (yes/no), obesity (yes/no according to a body mass index of 30), and highly sensitive C reactive protein (hs-CRP) (mg/L). On the hypothesis of possible non-linear relationship between peripheral inflammation and brain perfusion, a second analysis was performed between groups according to a hs-CRP threshold  $< \text{or} \geq 3$  mg/L, including all other mentioned covariables.

We used the “proportional scaling” routine to check for individual variations in global brain perfusion. Positive and negative correlations/associations were searched for each variable using SPM (T) maps at a height threshold voxel-level significance of  $p < 0.001$ , uncorrected, with a cluster extent of at least 80 voxels determined after Monte Carlo simulations. The perfusion values of each cluster were extracted at the individual level using MARSBAR (<http://marsbar.sourceforge.net/>). MNI coordinates were converted into Talairach coordinates, and brain structures were identified using the Talairach Daemon database (<http://ric.uthscsa.edu/projects/talairachdaemon.html>).

## Ethical concerns

The data collection was approved by the Commission Nationale de l'Informatique et des Libertés (CNIL number 1223715). The study was designed in accordance with the Declaration of Helsinki and French good clinical practice. All patients were informed of the study and gave written informed consent.

## Results

A total of 137 stabilized outpatients with schizophrenia were included in the study. The sample characteristics are presented in Table 1.

Table 1  
Socio-demographic and clinical variables of the 137 patients with schizophrenia.  
CDSS Calgary Depression Rating Scale.

<b>Socio-demographic characteristics</b>	
Sex (female) (N, %)	39 (28.5)
Age (years), (mean, SD)	36.02 (11.82)
Academic level (education level > 12 years) (N, %)	78 (56.9)
<b>Illness characteristics</b>	
Illness duration (years) (mean, SD)	13.40 (10.09)
Current illness severity (PANSS total score mean, SD)	76.31 (21.07)
Current major depressive disorder (CDSS score $\geq$ 6) (N, %)	37 (27.0)
<b>Treatment variables</b>	
Antidepressant treatment (N, %)	39 (28.5)
Daily antipsychotic dose (CPZ100eq) (mean, SD)	902.61 (693.48)
<b>Metabolic variables</b>	
Current daily tobacco smoking (N, %)	69 (50.4)
Body Mass Index (mean, SD)	26.47 (5.57)
Obesity (Body Mass Index $\geq$ 30)	34 (24.8)
C-reactive protein blood level (mg/L) (mean, SD)	3.74 (5.38)
C-reactive protein blood level $\geq$ 3mg/L	52 (38.0)

All significant SPECT results were found using  $p$ -voxel  $< 0.001$ , uncorrected, and a cluster size of at least 80 voxels (Fig. 1). The Table 2 lists the most significant voxels. A negative correlation was found between hs-CRP level and perfusion of 4 clusters: the right inferior frontal gyrus, the right middle/superior temporal gyrus, the left superior parietal lobe, and the right postcentral/transverse temporal gyrus. An increased perfusion of the left amygdala was found in patients with hs-CRP at least higher than 3 mg/L, in comparison to patients with hs-CRP level inferior to 3.

Table 2  
SPECT perfusion findings (p-voxel < 0.001, p-cluster < 0.05, k > 80; uncorrected).

	Cluster	voxel	Talairach coordinates			Localization
	k	T-score	x	y	z	
<b>Negative correlation between hs-CRP level and perfusion</b>	276	4.90	36	27	0	Right Inferior Frontal Gyrus, BA47
	324	4.70	53	-42	19	Right Superior Temporal Gyrus, BA13
		3.59	53	-60	14	Right Middle Temporal Gyrus, BA19
	228	4.07	-24	-64	46	Left Superior Parietal Lobule, BA7
	238	4.05	57	-15	19	Right Postcentral Gyrus, BA43
<b>Increased perfusion in patients with hs-CRP level <math>\geq</math> 3mg/L</b>	107	4.02	-22	-5	-23	Left Amygdala
<i>The k-value represents the number of voxels inside a particular cluster. Talairach coordinates are expressed in mm. BA: Brodmann Area.</i>						

The correlations of brain perfusion with psychotic and depressive symptomatology and hs-CRP blood levels are presented in Table 3. The perfusion of the right inferior frontal cluster was negatively correlated with global illness severity (PANSS total score), positive (PANSS positive factor), negative (PANSS negative factor) and excitement (PANSS excitement score) symptoms.

Table 3

Correlations of brain perfusion with psychotic and depressive symptomatology and highly sensitive C-reactive-protein (hs-CRP) blood levels. PANSS Positive and Negative Syndrome Scale for Schizophrenia. CDSS Calgary Depression Rating Scale. Hs-CRP: highly sensitive C-Reactive Protein. Significant correlations are in bold.

	Right Inferior Frontal Gyrus BA47		Right middle/superior temporal gyrus BA13 & BA19		Left superior parietal lobe BA7		Right postcentral and transverse temporal gyrus BA43		Left amygdala	
	Pearson	(p)	Pearson	(p)	Pearson	(p)	Pearson	(p)	Pearson	(p)
Illness severity (total PANSS score)	<b>-0.231</b>	<b>0.007</b>	0.022	0.800	0.012	0.890	-0.075	0.387	0.019	0.823
PANSS Positive factor	<b>-0.209</b>	<b>0.014</b>	0.134	0.119	-0.022	0.799	0.021	0.810	0.055	0.520
PANSS Negative factor	<b>-0.172</b>	<b>0.044</b>	0.002	0.982	0.017	0.842	-0.163	0.057	0.015	0.866
PANSS Excited factor	<b>-0.180</b>	<b>0.036</b>	-0.083	0.334	0.035	0.688	0.016	0.848	-0.068	0.427
PANSS Cognitive factor	-0.132	0.125	0.053	0.536	0.030	0.730	0.001	0.988	-0.078	0.366
PANSS Depressive factor	-0.080	0.351	-0.075	0.386	0.002	0.979	-0.037	0.667	0.101	0.241
CDSS depressive score	0.030	0.729	0.035	0.685	0.022	0.796	-0.032	0.709	0.136	0.114
Hs-CRP	<b>-0.371</b>	<b>&lt; 0.001</b>	<b>-0.215</b>	<b>0.011</b>	<b>-0.260</b>	<b>0.002</b>	<b>-0.293</b>	<b>0.001</b>	<b>0.221</b>	<b>0.009</b>

## Discussion

In stabilized outpatients with schizophrenia, peripheral inflammation was associated with brain perfusion changes of frontal, temporal and parietal regions. A negative correlation was found between perfusion of the right inferior frontal gyrus and persistence of psychotic symptoms under antipsychotic treatment, more specifically of positive, negative and excitement symptoms.

Peripheral inflammation was first negatively correlated with perfusion of the right fronto-temporal and bilateral parietal areas. Brain perfusion is a biomarker of global brain functioning through global synaptic activity. Peripheral inflammation induces microglial activation in the brain (the so-called neuroinflammation) [14], which has been extensively explored in schizophrenia in the last decade. In schizophrenia patients, peripheral inflammation can alter the blood-brain barrier, increasing its permeability and the impact on brain perfusion, supporting the “mild encephalitis” hypothesis of schizophrenia [15]. Neuroinflammation has been suggested to accelerate brain neuroprogression and ageing (the so-called “inflammaging” process) [16]. This neuro-progression may induce an

increase in the microglia density reported in post-mortem schizophrenia brain studies [17]. Based on our results, one could hypothesize that inflammation-associated brain perfusion changes may be the long-term consequence of the ongoing “brainflaming” process. This assumption is consistent with a mean illness duration of 13 years in our sample, while inflammation is often identified in the early phases of these illnesses [18], suggesting that the brains of the participants were probably exposed to chronic low-grade inflammation for several years.

The right inferior frontal gyrus was the only area which perfusion was correlated to both peripheral inflammation and persistence of positive symptoms under treatment. The frontal cortex is the richest brain area in dopaminergic neurons and is responsible for language processing and speech production, which has been recently demonstrated as a reliable marker of schizophrenia[19]. The right inferior frontal gyrus is also involved in the recognition of emotions of fear, disgust and anger[20]. Emotion recognition deficits, particularly to negative emotions, has been found as a useful predictor of schizophrenia risk[21]. This lobe is connected to prefrontal cortex that is involved in social interactions, which may explain the correlation between decreased perfusion of this area and increased emotional and social withdrawal[21]. Our patients were treated by antipsychotics, which suggests that frontal perfusion changes correlated to inflammation were also correlated to persistence of psychotic symptoms under treatment. The association of inflammation with persistence of psychotic symptoms under treatment has been well-established elsewhere[22], and anti-inflammatory strategies have shown effectiveness in improving schizophrenia symptomatology[23].

In addition, we found that the higher hs-CRP levels (those  $\geq 3\text{mg/L}$ ) were associated with increased perfusion of the left amygdala. This dose effect may be the result of a synergistic reaction of glutamate and quinolinic acid, a product of neuroinflammation [24]. Amygdala is classically associated with anxiety, which is poorly investigated in the schizophrenia scales. This may explain the absence of correlation between amygdala perfusion and psychotic symptomatology in our results. However, this result is consistent with amygdala alterations consistently found in patients with schizophrenia[25]. Changes in the perfusion of amygdala have been associated with increased bone-marrow activity, arterial inflammation and risk of later cardiovascular events in middle-aged men without identified disease[26]. Future studies should determine whether perfusion changes in amygdala perfusion of patients with schizophrenia may help predicting their risk of cardiovascular events, as this is the second cause of death in this population after 35 years[27].

While peripheral inflammation has been associated with depressive symptoms in schizophrenia[28], we found no significant association between brain perfusion of our 5 areas and depressive symptomatology. This suggests that other mechanisms may mediate the association between inflammation and depression in schizophrenia, e.g. diet, physical activity, physical illness or social isolation.

Strengths. Although the role of peripheral inflammation has been extensively explored in schizophrenia in the last two decades, its correlation with brain perfusion is reported for the first time in this study. All patients were assessed using the same protocol to limit heterogeneity. They were recruited through a large regional geographical area to limit the selection bias. Our results were adjusted for important confounding factors including age, sex, educational level, illness duration, antidepressant, chlorpromazine equivalent dose, tobacco smoking and obesity.

Limits and perspectives. Although our sample was large, enabling adjustment for multiple confounding factors, our results should be replicated in other populations including schizophrenia patients with different sociodemographic and illness characteristics. Our sample consisted of middle-aged patients with a mean illness duration that was quite long (approximately 13 years), suggesting that the brain perfusion changes in our results are probably the biomarkers of mid- to long-term inflammatory processes. Further explorations of earlier stages of the illness (such as early illness and the prodromic phase) may help understanding the illness trajectory associated with inflammatory processes in schizophrenia. It is well known that long-term inflammation is associated with cognitive impairment in

schizophrenia[29], however we did not carry out a cognitive test battery in the present study to explore the associations with cognitive impairment. Mitochondrial dysfunctions and oxidative stress could also participate to the observed brain perfusion abnormalities. Inflammatory disturbances are often associated with oxidative stress, however no marker of oxidative stress and mitochondrial dysfunction was available in daily practice. The question of the definition of low-grade peripheral inflammation remains open, other pro-inflammatory markers like IL-6, TNF and IL-1 would be potentially more prone to capture low-grade inflammation. However, these markers are not available in daily clinical practice.

## Conclusion

Peripheral inflammation is associated with changes of frontal, temporal and parietal regions in stabilized patients with schizophrenia. The perfusion of the right inferior frontal gyrus was negatively correlated with the persistence of positive, negative and excitement symptoms under antipsychotic treatment. As anti-inflammatory strategies have shown possible effectiveness in schizophrenia, future studies should determine whether such therapeutic intervention is mediated by brain perfusion changes, and consequently whether brain SPECT could be used as biomarker.

## Declarations

### Funding

None

### Conflicts of interest/Competing interests

The authors declare that they have no conflicts of interest

### Ethics approval

The retrospective observations required no ethical approval requirement other than informed consent.

### Consent to participate

Informed consent was obtained from all individual participants included in the study

### Consent for publication

Informed consent was obtained from all individual participants included in the study

### Availability of data and material

The SPECT data that support the findings are available from the corresponding author upon reasonable request

### Code availability

Not applicable


## References

1. Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. *Psychol*

- Med. 2016;46:3231–40.
2. Siskind D, Siskind V, Kisely S. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. *Can J Psychiatry*. 2017;706743717718167.
  3. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511:421–7.
  4. van Kesteren CFMG, Gremmels H, de Witte LD, Hol EM, Van Gool AR, Falkai PG, et al. Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. *Transl Psychiatry*. 2017;7:e1075.
  5. Sutterland AL, Fond G, Kuin A, Koeter MWJ, Lutter R, van Gool T, et al. Beyond the association. *Toxoplasma gondii* in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. *Acta Psychiatr Scand*. 2015;
  6. Orlovska-Waast S, Köhler-Forsberg O, Brix SW, Nordentoft M, Kondziella D, Krogh J, et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. *Mol Psychiatry*. 2019;24:869–87.
  7. Trépanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. *Mol Psychiatry*. 2016;21:1009–26.
  8. Sukumar N, Sabesan P, Anazodo U, Palaniyappan L. Neurovascular Uncoupling in Schizophrenia: A Bimodal Meta-Analysis of Brain Perfusion and Glucose Metabolism. *Front Psychiatry*. 2020;11:754.
  9. First M. Structured Clinical interview for the DSM-IV Axis I Disorders. American Psychiatric association; 1996.
  10. Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. *Schizophr Bull*. 2014;40:314–26.
  11. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13:261–76.
  12. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. *Schizophrenia research*. 1992;6:201–8.
  13. Fond G, Lançon C, Auquier P, Boyer L. C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review. *Front Psychiatry*. 2018;9:392.
  14. Marques TR, Ashok AH, Pillinger T, Veronese M, Turkheimer FE, Dazzan P, et al. Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies. *Psychol Med*. 2019;49:2186–96.
  15. Najjar S, Pahlajani S, De Sanctis V, Stern JNH, Najjar A, Chong D. Neurovascular Unit Dysfunction and Blood–Brain Barrier Hyperpermeability Contribute to Schizophrenia Neurobiology: A Theoretical Integration of Clinical and Experimental Evidence. *Front Psychiatry* [Internet]. 2017 [cited 2021 Feb 28];8. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440518/>
  16. Martínez-Cengotitabengoa M, Carrascón L, O'Brien JT, Díaz-Gutiérrez M-J, Bermúdez-Ampudia C, Sanada K, et al. Peripheral Inflammatory Parameters in Late-Life Depression: A Systematic Review. *Int J Mol Sci* [Internet]. 2016 [cited 2021 Feb 28];17. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187822/>
  17. Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. *Lancet Psychiatry*. 2015;2:258–70.
  18. Fraguas D, Díaz-Caneja CM, Ayora M, Hernández-Álvarez F, Rodríguez-Quiroga A, Recio S, et al. Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. *Schizophr Bull*. 2019;45:742–51.
  19. Corcoran CM, Carrillo F, Fernández-Slezak D, Bedi G, Klim C, Javitt DC, et al. Prediction of psychosis across protocols and risk cohorts using automated language analysis. *World Psychiatry*. 2018;17:67–75.

20. Sprengelmeyer R, Rausch M, Eysel UT, Przuntek H. Neural structures associated with recognition of facial expressions of basic emotions. *Proc Biol Sci.* 1998;265:1927–31.
21. Martin D, Croft J, Pitt A, Strelchuk D, Sullivan S, Zammit S. Systematic review and meta-analysis of the relationship between genetic risk for schizophrenia and facial emotion recognition. *Schizophr Res.* 2020;218:7–13.
22. Potkin SG, Kane JM, Correll CU, Lindenmayer J-P, Agid O, Marder SR, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. *NPJ Schizophr.* 2020;6:1.
23. Çakici N, van Beveren NJM, Judge-Hundal G, Koola MM, Sommer IEC. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. *Psychol Med.* 2019;49:2307–19.
24. Dantzer R, Walker AK. Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression? *J Neural Transm.* 2014;121:925–32.
25. Ho NF, Li Hui Chong P, Lee DR, Chew QH, Chen G, Sim K. The Amygdala in Schizophrenia and Bipolar Disorder: A Synthesis of Structural MRI, Diffusion Tensor Imaging, and Resting-State Functional Connectivity Findings. *Harv Rev Psychiatry.* 2019;27:150–64.
26. Tawakol A, Ishai A, Takx RA, Figueroa AL, Ali A, Kaiser Y, et al. Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. *Lancet.* 2017;389:834–45.
27. Samaras K, Correll CU, Curtis J. Premature Mortality and Schizophrenia-The Need to Heal Right From the Start. *JAMA Psychiatry.* 2016;
28. Fond G, Faugere M, Richieri R, Cermolacce M, Korchia T, Micoulaud-Franchi JA, et al. Depressive symptoms and chronic peripheral inflammation are associated with impaired functional remission in schizophrenia independently of psychotic remission. *J Affect Disord.* 2021;280:267–71.
29. Bora E. Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis. *Psychol Med.* 2019;49:1971–9.

## Figures



**Figure 1**

SPECT perfusion findings ( $p$ -voxel  $< 0.001$ ,  $p$ -cluster  $< 0.05$ ,  $k > 80$ ; uncorrected). Hs-CRP: highly sensitive C-Reactive Protein. A. Negative correlation between hs-CRP level and perfusion: Right Inferior Frontal Gyrus BA47, Right middle/superior temporal gyrus BA13 & BA19, Left superior parietal lobe BA7, Right postcentral and transverse temporal gyrus BA43 B. Increased perfusion in patients with hs-CRP level  $\geq 3$ mg/L: Left amygdala